Where relevant, the presentation will be webcast live and can be accessed by visiting ‘Events & Presentations’, under ‘Events’, via the ‘Investors’ section of Immunocore’s website at ...
Among 5-year survivors in the tebentafusp arm, 44% received tebentafusp as their only therapy. In contrast, 86% of control ...
Needham has initiated coverage on Immunocore Holdings Plc IMCR with a Buy rating and a price target of $75. Needham analyst Gil Blum says Immunocore has achieved a significant milestone as the pioneer ...
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, 3 June 2023) Immunocore (IMCR) Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel ...
Immunocore (IMCR) announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Immunocore Holdings (NASDAQ:IMCR) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table encapsulates their ...
Immunocore (NASDAQ:IMCR) executives highlighted the company’s T-cell receptor (TCR) platform, commercial momentum for ...
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response Data were ...
Immunocore Hldgs (NASDAQ:IMCR) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the ...
Immunocore to report second quarter 2024 financial results and host call on August 8, 2024 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 01 August 2024) Immunocore Holdings plc ...
Revenue (GAAP) rose 30% to $98.0 million in the quarter, topping GAAP revenue estimates by $5.85 million. Earnings per share (GAAP) of $(0.20) missed GAAP EPS estimates due to higher R&D and SG&A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results